Onercept

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Immunoregulatory active, genetically engineered, recombinant, unmodified form of the soluble TNF-alpha-receptor type I (p55).

Pharmacodynamics (Effect)This section has been translated automatically.

High affinity binding of soluble TNF-alpha receptor type 1 molecules to TNF-alpha. This neutralizes the bound TNF-alpha molecules and makes them physiologically ineffective.

Field of application/useThis section has been translated automatically.

Not yet approved at present. Hopeful substance in the pipeline. According to Phase II registration studies (manufacturer's data), it is effective in psoriasis vulgaris, psoriatic arthritis and Crohn's disease. The results of phase III and IV studies remain to be seen.

LiteratureThis section has been translated automatically.

  1. Gladman DD (2004) Psoriatic arthritis. Dermatol Ther 17: 350-363
  2. Nikas SN, Drosos AA (2003) Onercept. Serono. Curr Opin Investig Drugs 4: 1369-1376

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer